Pfizer's JAK Inhibitor Xeljanz Approved, Set to Launch in RA
Pfizer Inc. is wasting no time with the rollout of its Janus kinase (JAK) inhibitor tofacitinib, branded Xeljanz, which gained FDA approval late Tuesday for adults with moderate to severely active rheumatoid arthritis (RA).
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter